Epoetin alfa biosimilar - Sandoz

Drug Profile

Epoetin alfa biosimilar - Sandoz

Alternative Names: Abseamed; Aczicrit; Binocrit; Epoetin alfa Hexal; Epoetin lambda - Sandoz; Grandicrit; HX 575; HX 575 epoetin alfa; HX 575, recombinant epoetin alfa; Novicrit

Latest Information Update: 02 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sandoz
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 12 Feb 2015 Launched for Anaemia in Russia (SC)
  • 01 Jan 2015 Sandoz completes the phase III ACCESS trial for Anaemia in USA (NCT01693029)
  • 01 Oct 2014 Sandoz completes the phase III SENSE trial in Anaemia in Germany, Italy, Romania, Russia, Turkey, Ukraine and Poland (NCT01576341; EudraCT2011-002871-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top